Kiniksa Pharmaceuticals International vs Liquidia
KNSA and LQDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KNSA and LQDA compare
Kiniksa Pharmaceuticals International is the larger company, worth 2.9 times as much as Liquidia ($14.9B against $5.1B).
On earnings, Liquidia is cheaper: it trades at 40.8× trailing earnings, against 73.2× for Kiniksa Pharmaceuticals International.
Liquidia grew revenue faster over the last twelve months (2234% versus 58.2% for Kiniksa Pharmaceuticals International).
Liquidia keeps more of each dollar of sales as profit, with a net margin of 30.7% compared with 11.6% at Kiniksa Pharmaceuticals International.
Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 8 for Liquidia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KNSA | LQDA |
|---|---|---|
| Size and price | ||
| Market cap | $14.9B | $5.1B |
| Share price | $95.11 | $56.73 |
| Change, 1 year | 136% | 102% |
| Change, 5 years | 716% | 1280% |
| Beta (5Y) | 0.15 | 1.00 |
| Employees | 366 | 216 |
| StockData Score | ||
| Total score | 14 (better) | 8 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 4 (better) | 3 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 73.2× | 40.8× (better) |
| P/S | 15.8× | 11.3× (better) |
| P/B | 21.0× (better) | 26.0× |
| EV/EBITDA | 109× | 28.2× (better) |
| P/FCF | 75.8× | 33.7× (better) |
| FCF yield | 1.3% | 3.0% (better) |
| Fair value | $16.72 | $32.46 |
| Margin of safety | −469% | −74.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 58.2% | 2234% (better) |
| Revenue growth, 5Y average | – | 192% |
| Net income growth (TTM) | 205% | – |
| EPS growth (TTM) | 189% | – |
| Profitability | ||
| Gross margin | 90.2% | – |
| Operating margin | 13.8% | 37.4% (better) |
| Net margin | 11.6% | 30.7% (better) |
| FCF margin | 20.8% | 33.4% (better) |
| Return on equity | 17.6% | 132% (better) |
| Return on invested capital | 60.2% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | 6.3× |
| Current ratio | 3.91 (better) | 2.31 |
| Altman Z-score | 34.40 (better) | 10.49 |
| Piotroski F-score | 8 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 29.9% | 81.1% |
| Held by insiders | 5.1% | 19.5% |
| Insider net buying, 12 months | −$122M (better) | −$227M |
| Short interest, % of float | 2.9% | 24.3% |
Go deeper
- KNSA stock overview
- KNSA income statement
- KNSA valuation and score
- LQDA stock overview
- LQDA income statement
- LQDA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.